Build

Article Backlog (priority queue for the Article Engine)

33 min read

Article Backlog

Prioritised queue for the daily Article Engine. P0 = urgent (breakthrough news), P1 = high value & we have the sources, P2 = solid, P3 = nice-to-have. The engine takes the top unblocked item, writes it, then deletes it from this list and logs it in Pipeline Log.md. The Research Radar appends new items (usually P0/P1).

Each item: - [Pn] Working title — archetype — key sources (atomic notes) — primary keyword

Queue

  • [P0] The FDA Peptide 503A Review: What the July 2026 PCAC Vote Means for BPC-157, TB-500 & MOTS-c — news/compliance explainer — SOURCE-fda-pcac-503a-peptide-review-2026, BPC-157, TB-500, MOTS-C, Research-Use-Only, COA — “fda peptide reclassification 2026” / “bpc-157 fda 503a”
    • NOTE (2026-07-01 radar): breakthrough regulatory news, meeting ~3 weeks out. The story = the Feb-2026 HHS/RFK Category-2 removal of ~12 peptides + the July 23–24 2026 PCAC vote on adding 7 (BPC-157, TB-500, MOTS-c, KPV on the 23rd; DSIP/Emideltide, Semax, Epitalon on the 24th) to the §503A compounding bulk-list — with FDA’s own evaluated uses (BPC-157 = ulcerative colitis, TB-500/KPV = wound healing, MOTS-c = obesity & osteoporosis), a strong research-literacy angle vs the athletic-recovery marketing framing. Huge commercial + search interest and the trust/compliance pillar’s biggest 2026 story. Compliance-critical: frame “reviewed ≠ approved ≠ proven,” PCAC is advisory/non-binding, everything stays research-use-only, no medical/treatment advice, no “now legal, buy now” framing. Links ⇄ does-phase-3-mean-approved, does-tb-500-have-human-trials, how-to-read-a-peptide-coa, bpc-157-clinical-trial-first-human-rct, tb-500-clinical-trial-first-human-cardiovascular; products bpc-157, tb-500, mots-c, kpv, epithalon, semax, dsip. Fast-lane to update the moment the PCAC votes (Jul 24) and again if FDA moves to rulemaking.
  • [P1] BPC-157 Research Protocol: Routes, Dosing, Timing & Cycling — protocol guide — BPC-157, TRANSCRIPT-bpc157-deep-dive, Animal-to-Human Dose Conversion — “bpc-157 dosage”
    • NOTE (2026-06-04 engine): skipped this run — high cannibalization risk vs existing bpc-157-complete-guide-2026-benefits-dosing and yesterday’s dr-koniver-bpc-157-protocol-tissue-repair. Either re-scope to a distinct angle (e.g. routes & oral-vs-SubQ bioavailability) or fold into the complete guide before writing.
  • [P2] SS-31 / Elamipretide: The Mitochondrial Peptide Explained — peptide guide — SS-31, PAPER-szeto-2014-first-in-class-cardiolipin, Mitochondrial Bioenergetics — “ss-31 elamipretide”
    • NOTE (2026-06-14 engine): skipped — high cannibalization vs 3 existing SS-31 articles (ss-31-elamipretide-mitochondrial-protection, ss-31-longevity-mitochondria-protection, ss-31-peptide-guide-cellular-energy-anti-aging-cardiac-2026). Re-scope to a distinct angle (e.g. SS-31 vs MOTS-C is already written too — try “elamipretide clinical trial results” news-anchored) or retire.
  • [P2] Tesamorelin vs CJC-1295/Ipamorelin for Visceral Fat — comparison — Tesamorelin, PAPER-falutz-2007-metabolic-effects-of, PAPER-stanley-2014-effects-of-tesamorelin-on — “tesamorelin visceral fat”
    • NOTE (2026-06-14 engine): overlaps existing tesamorelin-vs-ipamorelin-fat-loss-comparison (same Falutz-2007/Stanley-2014 papers, same visceral-fat framing). To survive, the distinct hook must be the CJC-1295 stack (GHRH+GHRP) vs tesamorelin-alone, not tesa-vs-ipa again — otherwise fold into the existing comparison.
  • [P2] GHK-Cu for Skin & Hair: Mechanism, Forms & Research Protocols — peptide guide — GHK-Cu, PAPER-pickart-2018-regenerative-and-protective-actions, TRANSCRIPT-ghk-cu-deep-dive — “ghk-cu benefits”
    • NOTE (2026-06-14 engine): skipped — heavily cannibalized (5 existing GHK-Cu articles incl. anti-aging, hair-growth, vs-retinol, raw-powder). Needs a genuinely new angle or retire.
  • [P2] Epitalon & Telomeres: What the Khavinson Research Shows — peptide guide — Epithalon, PAPER-khavinson-2003-epithalon-peptide-induces-telomerase, PAPER-blackburn-2015-human-telomere-biology — “epitalon telomeres”
    • NOTE (2026-06-14 engine): skipped — 3 existing Epithalon articles already cover telomerase/longevity/dosing. Re-scope or retire.
  • [P3] Healing & Recovery Peptides (Pillar Hub) — pillar — STACK-healing, BPC-157, TB-500, GHK-Cu — “healing peptides”
  • [P3] Longevity Peptides 2026: The Evidence-Ranked Guide — comparison/pillar — STACK-longevity, Epithalon, SS-31, MOTS-C — “best longevity peptides”

Ideas discovered (2026-07-01 radar run)

  • [P1] Survodutide vs the Field: Where the Glucagon/GLP-1 Dual Agonist Lands (SYNCHRONIZE-1) — news/comparison — Survodutide, SOURCE-survodutide-synchronize1-phase3-2026, Glucagon Agonism — “survodutide weight loss” / “survodutide vs tirzepatide” (first Phase 3 obesity readout: 16.6% weight loss but standout liver fat −63% / visceral −34%, presented ADA 2026 + published NEJM/Nature Medicine; adds a new row to best-glp-1-for-weight-loss-2026-ranked and a MASLD/liver-fat angle the class pages lack; distinct from the retatrutide/tirzepatide head-to-heads; links ⇄ best-glp-1-for-weight-loss-2026-ranked, how-glp-1-works-for-weight-loss, retatrutide-vs-tirzepatide-comparison-2026; products survodutide, retatrutide, tirzepatide)
  • [P1] Can GLP-1s Prevent Breast Cancer? The 2026 Incidence Data, Honestly Graded — news/research-literacy — Semaglutide, Tirzepatide, SOURCE-glp1-breast-cancer-incidence-mcdonald-2026, GLP-1 Agonism — “glp-1 breast cancer prevention” / “does ozempic lower cancer risk” (the NEW incidence/prevention axis — 94,827 cancer-free women, ~25–37% lower odds, reportedly weight-loss-independent, ASCO 2026 Abstract 10506 / JCO Oncology Practice — distinct from the existing glp-1-cancer-risk-what-2026-research-shows which covers safety + progression-in-patients; strong “not weight loss” hook, but must hold the observational line (association ≠ prevention, not a recommendation); Research-Literacy/oncology sibling; links ⇄ glp-1-cancer-risk-what-2026-research-shows, how-glp-1-works-for-weight-loss, does-phase-3-mean-approved; products semaglutide, tirzepatide, retatrutide)
  • [P2] MOTS-c Enters Human Trials: Inside the First Prediabetes RCT (NCT07505745) — news/research-literacy — MOTS-C, SOURCE-motsc-prediabetes-phase2a-nct07505745, Mitochondrial Bioenergetics — “mots-c clinical trial” / “mots-c human study” (the “registered but unreported” first human RCT of a mitochondrial-derived peptide — Phase 2a, insulin-sensitivity endpoint; the sibling to the BPC-157/TB-500 first-human-trial pieces, and it pairs naturally with the FDA-503A piece since MOTS-c is simultaneously on the July agenda for obesity & osteoporosis; fast-lane to P0 if it reads out positive; links ⇄ the FDA-503A piece, peptide-stack-for-fat-loss-glp1-gh-mots-c; product mots-c)
  • NOTE: Retatrutide TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (established CVD) are still pending as of 2026-07-01 — the P1 “Retatrutide TRIUMPH-2 & TRIUMPH-3” fast-lane item (2026-06-16 block) stays queued; take it the moment either reads out.
  • NOTE: the SS-31/elamipretide FORZINITY (Barth) accelerated approval (Sept 2025) is already in the KB (SS-31 note); a new formal review (PMID 41260682, 2026) is corroboration only → no new source note warranted; cite it if an SS-31 news article is ever written.

Ideas discovered (2026-06-28 engine, while writing does-phase-3-mean-approved)

  • [P2] Primary vs Surrogate Endpoints: Why “Improved a Biomarker” Isn’t “Helped a Patient” — research-literacy explainer — COA, Animal-to-Human Dose Conversion — “surrogate endpoint vs clinical outcome” / “what is a surrogate endpoint” (the natural deepening of Question 2 of the Phase-3 test: even an endpoint that’s met may be a SURROGATE — A1C, body weight, a biomarker — not a hard clinical OUTCOME like events or mortality; this is exactly the “does the weight win translate to fewer events” gap the GLP-1 head-to-heads keep flagging (semaglutide’s SELECT/FLOW CV+kidney wins vs tirzepatide’s not-yet-proven outcomes), and the “safety biomarker, not efficacy” status of the TB-500 NCT07487363 trial; clean Research-Literacy spoke that the whole Fat-Loss head-to-head sub-cluster AND every trial piece can link UP to; sibling to does-phase-3-mean-approved; multiple consumers already — strong P2)
  • [P3] What “Statistically Significant” Actually Means: p-values, Power & Why p=0.0656 Is a Miss — research-literacy explainer — Animal-to-Human Dose Conversion, COA — “what does statistically significant mean” / “p value explained” (the statistics half of Question 2 the Phase-3 piece leans on but only states: the p<0.05 convention, why a near-miss (SEER-1’s 0.0656) is still a miss, underpowering/small-n, confidence intervals, and multiplicity — why 20 secondary endpoints will throw a “significant” one by chance; high-PAA evergreen literacy keyword competitors answer abstractly; teaches readers to demand the primary p-value; links ⇄ does-phase-3-mean-approved, does-tb-500-have-human-trials, rgn-259-thymosin-beta-4-eye-drops, how-to-read-peptide-studies-animal-to-human-dose-conversion)
  • NOTE: the Research-Literacy/Trust pillar is now a clean quartet — how-to-read-peptide-studies-animal-to-human-dose-conversion (read the dose) ⇄ how-to-read-a-peptide-coa-hplc-purity-vs-identity (read the source/identity) ⇄ does-tb-500-have-human-trials (apply both to one peptide) ⇄ does-phase-3-mean-approved (grade the trial’s stage & result). The long-pending [P3] “How to Read a ClinicalTrials.gov Record” (2026-06-17 block) and [P3] “Open-Label vs Double-Blind” (2026-06-21 block) each gained ANOTHER consumer here (registered≠proven; press-release≠peer-review) → both are now strong bump-to-P2 candidates as the next literacy spokes. On their next edit, does-tb-500-have-human-trials, rgn-259-thymosin-beta-4-eye-drops, tb-500-clinical-trial-first-human-cardiovascular, bpc-157-clinical-trial-first-human-rct, and retatrutide-phase-3-results-triumph-1 should each add an UP-link to the new does-phase-3-mean-approved spoke (all use “Phase 3”/“registered” language in passing).

Ideas discovered (2026-06-27 engine, while writing does-tb-500-have-human-trials)

  • [DONE 2026-06-28 engine] Phase 3 ≠ Approved: Why a Trial’s Stage Isn’t Its Success — WRITTEN as does-phase-3-mean-approved (title “Does Phase 3 Mean Approved? Stage Isn’t Success”, keyword “does phase 3 mean approved”). Promoted the 3rd axis of the does-tb-500 question test to a standalone evergreen Research-Literacy/trust spoke the whole site links UP to: a phase-ladder table of what each phase tests (FDA Step 3), the stage-vs-success thesis (a completed trial can miss its primary endpoint — SEER-1 p=0.0656 / SEER-3 failed), the success-rate arithmetic (BIO 2011-2020 LOA-from-Phase-1 = 7.9%; FDA ~70% clear Ph1 / ~33% Ph2→Ph3; ~half of Phase-3 drugs still fail; Wong 2019 ~13.8% overall, 3.4% oncology), a “clinically studied”≠“clinically proven” weasel-phrase decode (Murphy 2023 — readers misremember “studied” as “proven”; “clinically proven” has no standard legal definition), and a 5-QUESTION TEST (stage+finished? / primary endpoint met? / peer-review vs press-release? / approved-by-whom-for-what? / same-molecule+route?). Distinct from how-to-read-peptide-studies (dose conversion) and how-to-read-a-peptide-coa (sourcing/identity) by being the trial-evidence-grading spoke. Links ⇄ does-tb-500-have-human-trials, rgn-259-thymosin-beta-4-eye-drops, tb-500-clinical-trial-first-human-cardiovascular, retatrutide-phase-3-results-triumph-1, how-to-read-peptide-studies-animal-to-human-dose-conversion, how-to-read-a-peptide-coa-hplc-purity-vs-identity, peptide-side-effects-safety-guide-2026. Products: tb-500, bpc-157, retatrutide.
  • [P3] Peptides Banned in Sport: The WADA S2 Growth-Factor List (TB-500, BPC-157, GH Secretagogues) — compliance/trust explainer — TB-500, Research-Use-Only — “is tb-500 banned wada” / “peptides banned in sport” (the WADA S2.3 growth-factor angle the TB-500 piece raised in one line — which research peptides are prohibited at all times, the ~30–45-day TB-500 detection window, two-to-four-year sanctions, the horse-racing origin; high commercial-intent for any tested athlete; clean trust-pillar spoke that every athlete-facing peptide page can link to; products tb-500, bpc-157)
  • [P3] Recombinant Thymosin β4 for Heart Attack: The Phase 1 Building Toward an MI Trial — news/mechanism explainer — TB-500, PAPER-bock-marquette-2004-thymosin-beta4-activates-integrin — “thymosin beta 4 heart attack” (the full-length TB4 systemic program the does-tb-500 piece flagged as distinct from the fragment’s CV trial: Wang 2021 first-in-human IV Phase 1 PMID 34346165 — 54 SAD + 30 MAD, no DLT, no tumorigenesis at 6mo — was explicitly a stepping stone toward an acute-MI study, anchored on Bock-Marquette 2004 Nature cardiac-repair rationale; the “full protein going to the heart” story vs the “fragment CV safety trial” NCT07487363; sibling to tb-500-clinical-trial-first-human-cardiovascular and the pending “why a tissue-repair peptide is tested in heart disease” idea; product tb-500)
  • NOTE: with does-tb-500-have-human-trials written, the Healing/β4 sub-cluster is now a clean quartet: tb4-vs-tb-500 (identity) ⇄ rgn-259-thymosin-beta-4-eye-drops (the ocular human data) ⇄ tb-500-clinical-trial-first-human-cardiovascular (the fragment’s one trial) ⇄ does-tb-500-have-human-trials (the question-page HUB synthesising all three). The hub should get an UP-link added to it from tb4-vs-tb-500 and tb-500-thymosin-beta-4-healing-research on their next edit (both answer “does it have human data” in passing). The new [P2] “Phase 3 ≠ Approved” literacy spoke is the best next unblocked trust-pillar piece.

Ideas discovered (2026-06-26 engine, while writing growth-hormone-peptide-timing)

  • [P3] Sleep Quality and Growth Hormone: Does Poor Sleep Sabotage a GH Peptide Protocol? — explainer — Somatostatin, DSIP, Melatonin, PAPER-vancauter-1996-physiology-of-growth-hormone — “sleep and growth hormone” (the direct corollary of the timing piece’s primary data: Takahashi 1968 showed the pulse tracks sleep onset and Van Cauter 1996 that ~70% of nocturnal GH coincides with slow-wave sleep — so if you don’t actually reach deep sleep, a perfectly-timed peptide pulse lands in a shallow window and underperforms; ties the GH-Axis cluster to sleep hygiene + the sleep catalog (DSIP, melatonin); clean spoke linking ⇄ growth-hormone-peptide-timing, dsip-delta-sleep-inducing-peptide-research, ghrh-ghrp-synergy-why-stack-gh-peptides; products dsip, melatonin, sermorelin, ipamorelin)
  • [P3] Does Exercise Timing Boost GH Peptide Results? The Workout Pulse — explainer — GH Secretagogue, TRANSCRIPT-gh-peptide-administration-deep-dive — “exercise growth hormone peptide” (the second-dose / exercise-driven-pulse material the timing piece compressed into one paragraph: the fasted pre-workout window, above-lactate-threshold aerobic, big-compound-lift / short-rest resistance, and why a late-afternoon workout dose collides with the night dose; natural daytime-pulse clocks men ~noon/6pm, women ~11am/4pm; clean spoke under growth-hormone-peptide-timing; products ipamorelin, cjc-1295-no-dac, cjc-1295-no-dac-ipamorelin)
  • [P3] Recombinant HGH vs GH Peptides: Why the Best Dosing Time Is Almost Opposite — comparison/explainer — GH Secretagogue, HGH — “when to take hgh injection” (the secretagogue-amplifies-your-pulse vs rhGH-replaces-it timing distinction the piece raised in one section; anchored on Levshtein 2025 PMID 40034226 — morning vs evening rhGH comparable for growth/IGF-1 but evening better mimics diurnal pattern — vs the secretagogue night-dose-to-ride-the-pulse logic; deepens hgh-peptide-therapy-benefits-risks-vs-secretagogues-2026; products hgh, sermorelin, ipamorelin)
  • NOTE: the timing piece is now a SECOND consumer of both pending GH-Axis concept ideas — [P3] “Somatostatin: The GH Brake” (2026-06-25 block) and [P3] “Basal vs Pulsatile GH” (2026-06-24 block). Both are invoked heavily here (somatostatin nadir is the #1 night-dosing reason; amplitude-vs-baseline is the long-acting exception) → consider bumping both to P2 as the next GH-Axis concept spokes the whole cluster links up to.

Ideas discovered (2026-06-23 engine, while writing tirzepatide-vs-semaglutide-diabetes-surpass-2)

  • [P3] Semaglutide 2.0 mg vs 1.0 mg: Does the High Diabetes Dose Close the Tirzepatide Gap? — evidence/explainer — Semaglutide, Tirzepatide — “semaglutide 2 mg vs 1 mg” (the fair-dose caveat the SURPASS-2 piece had to raise: SURPASS-2 beat sema 1 mg, but SUSTAIN FORTE later approved 2.0 mg with more A1C + weight — yet 2.0 mg has never been run head-to-head vs tirzepatide; high-intent “is 2 mg Ozempic worth it” keyword; honest “would narrow, likely not reverse the 15 mg margin” framing; clean spoke under tirzepatide-vs-semaglutide-diabetes-surpass-2; products semaglutide, tirzepatide)
  • NOTE: the long-pending [P3] “Treatment-Regimen vs Efficacy Estimand” literacy idea (2026-06-20 block) gained another consumer — SURPASS-2’s headline figures differ across sources (NEJM treatment-regimen vs Lilly-release efficacy estimand) for exactly this reason; now referenced by both the ranking hub and this diabetes head-to-head → consider bumping it to P2.
  • NOTE: Fat Loss / Metabolic now has a matched head-to-head pair — obesity (tirzepatide-vs-semaglutide-surmount-5) + diabetes (tirzepatide-vs-semaglutide-diabetes-surpass-2). When semaglutide 2.0 mg or a tirzepatide CV/kidney-outcome trial reads out, update BOTH (and the best-glp-1 hub) rather than only writing fresh — the “does the weight win translate to fewer events” gap is the standing open question both pieces flag.

Ideas discovered (2026-06-22 engine, while writing rgn-259-thymosin-beta-4-eye-drops)

  • [DONE 2026-06-27 engine] Does TB-500 Have Human Data? What the Trials Actually Show — WRITTEN as does-tb-500-have-human-trials (title “Does TB-500 Have Human Trials? The 2026 Evidence”, keyword “does tb-500 have human trials”). Built the cluster’s question-page HUB: a single sorted evidence table covering EVERY human study cited for “TB-500” (RGN-259 ocular Phase 3 SEER-1 miss p=0.0656 / SEER-3 fail / ARISE mixed; recombinant full-length TB4 IV Phase 1 Wang 2021 PMID 34346165 — safety only; ~10-pt cardiac stem-cell + ~73-pt dermal pilots [educational/secondary]; the fragment’s animal-only MSK reputation; NCT07487363 CV safety, no results), then a 3-question literacy test (same molecule? same route? endpoint met?) that every cited “human trial” fails ≥1 — the empty cell (injected fragment × finished efficacy trial) is the answer. Distinct from rgn-259 (one molecule) and tb-500-clinical-trial (one trial) by being the synthesis hub above both. Added WADA S2 + not-FDA-approved + mass-spec/COA sourcing + a “what a real TB-500 human trial would have to show” forward-looking section. Deliberately omitted an unverified single-snippet “FDA compounding advisory committee July 23 2026” claim (couldn’t corroborate). Products: tb-500, bpc-157-tb-500, bpc-157, thymosin-alpha-1.
  • [P3] Why “Failed” Rare-Disease Trials Aren’t Always Failed Drugs: The Placebo-Effect Problem in Neurotrophic Keratopathy — research-literacy explainer — COA, Animal-to-Human Dose Conversion — “placebo effect clinical trials” (the SEER-3 miss the RGN-259 piece attributed to a stronger-than-expected placebo arm — some NK patients heal on vehicle drops alone — is a clean teaching case for why small/early positive trends (SEER-1 p=0.0656) fail to replicate, and why a missed endpoint ≠ a useless drug; Research-Literacy-pillar sibling to how-to-read-peptide-studies; every news-anchored trial article can link UP to it)
  • [P3] Thymosin β4 for Dry Eye: The ARISE Phase 3 Program, Honestly Graded — evidence/explainer — TB-500, Thymosin Alpha-1 — “thymosin beta 4 dry eye” (the >1,600-patient ARISE-1/2/3 dry-eye program the RGN-259 piece compresses into one section — the mixed sign/symptom-endpoint record, the FDA dual-endpoint bar for dry eye, why “Phase 3” didn’t become an approval; deepens the ocular-β4 story without re-litigating the fragment distinction; product tb-500)

Ideas discovered (2026-06-15 radar run)

  • [DONE 2026-06-17 engine] The First Human BPC-157 Trial: Inside the Hamstring-Strain RCT (NCT07437547) — WRITTEN as bpc-157-clinical-trial-first-human-rct (title “BPC-157 Clinical Trial: The First Human RCT (2026)”, keyword “bpc-157 clinical trial”). Decoded the registered double-blind placebo-controlled Phase 2 design (subQ ×14d + rehab; co-primary MRI injury-volume + return-to-sport), framed honestly against the thin prior base and the cancelled-2015 Phase 1, with the TB-500-first-trial parallel. FAST-LANE to P0 the moment NCT07437547 posts results — convert this from “registered but unreported” to a results piece.
  • [DONE 2026-06-18 engine] TB-500’s First Human Trial Is Cardiovascular, Not Musculoskeletal (NCT07487363) — WRITTEN as tb-500-clinical-trial-first-human-cardiovascular (title “TB-500 Clinical Trial: The First Human Study (2026)”, keyword “tb-500 clinical trial”). Decoded the registered Phase 1/2 placebo-controlled dose-escalation safety study in stable ASCVD; explained the “why the heart, not a hamstring” surprise via actin/angiogenesis + the Bock-Marquette-2004 cardiac rationale; carried the fragment-≠-full-length-TB4 caveat (this trial can’t validate the RGN-259 ocular Phase 3 / first-in-human TB4 Phase 1, which used full-length protein); paired it with the BPC-157 trial piece as the “2026: peptides enter human trials” sibling. FAST-LANE to P0 the moment NCT07487363 posts results.
  • [DONE 2026-06-19 engine] Orforglipron (Foundayo) Is Here — WRITTEN as orforglipron-foundayo-oral-glp-1-pill (title “Orforglipron (Foundayo): The First Oral GLP-1 Pill (2026)”, keyword “orforglipron”). Consolidated both orforglipron backlog items (this P2 news piece + the 2026-06-13 P2 “Oral Semaglutide vs Orforglipron” mechanism item, now also retired): the SNAC/oral-sema-vs-small-molecule divide is a core H2 here. Anchored on ATTAIN-1 (NEJM, −11.2%/72wk @36mg), ACHIEVE-3 (Lancet head-to-head — with the honest “beat only the low 7/14mg diabetes doses” caveat), OASIS-1 (oral sema 50mg −15.1%), the FDA approval, and Drucker mechanism. Verdict framed as convenience-not-magnitude; orforglipron kept as contrast-only (not a catalog product).

Ideas discovered (2026-06-19 engine, while writing orforglipron-foundayo-oral-glp-1-pill)

  • [P2] Orforglipron ATTAIN-2 / Cardiovascular Outcomes: The Next Oral-GLP-1 Shoe — news-anchored follow-up — GLP-1 Agonism, Semaglutide — “orforglipron cardiovascular outcomes” (fast-lane when ATTAIN-2/diabetes or a CVOT reads out; the #1 gap flagged in today’s piece is orforglipron’s missing hard-outcome data vs injectable semaglutide’s SELECT/FLOW/heart-failure wins — the moment orforglipron posts outcome data, the convenience-vs-magnitude verdict updates; links ⇄ orforglipron-foundayo-oral-glp-1-pill, glp-1-cancer-risk-what-2026-research-shows; orforglipron contrast-only, products semaglutide)
  • [P3] Why Pfizer’s Danuglipron Was Pulled: The Non-Peptide GLP-1 Liver Question — safety/trust explainer — GLP-1 Agonism, Research-Use-Only — “danuglipron liver” / “non-peptide glp-1 safety” (the CYP3A4 / oxidative-metabolite / two-candidates-withdrawn-for-hepatotoxicity angle this article had to compress into one paragraph; the small-molecule-specific risk that peptides don’t carry; clean safety spoke under the orforglipron piece, reinforces the peptide-safety pillar)
  • [CONSUMED 2026-06-20 engine] GLP-1 Weight-Loss Class Ranking now needs an oral tier — folded into best-glp-1-for-weight-loss-2026-ranked: orforglipron (~11%) is the 6th row beneath oral sema (~15.1%) / subQ sema (~14.9%, 18.7% @7.2mg) / CagriSema (~20.4%) / tirzepatide (~22.5%) / retatrutide (~28.3%), linked ⇄ orforglipron-foundayo-oral-glp-1-pill.

Ideas discovered (2026-06-20 engine, while writing best-glp-1-for-weight-loss-2026-ranked)

  • [DONE 2026-06-21 engine] SURMOUNT-5: The Only Head-to-Head — Tirzepatide vs Semaglutide for Weight Loss — WRITTEN as tirzepatide-vs-semaglutide-surmount-5 (title “Tirzepatide vs Semaglutide: SURMOUNT-5 Head-to-Head”, keyword “tirzepatide vs semaglutide”). Built the dedicated head-to-head decision page the ranking hub kept pointing at: SURMOUNT-5 (NEJMoa2410819, Phase 3b open-label, 751 no-diabetes pts) at max-vs-max obesity doses (tirz 10/15mg vs sema 1.7/2.4mg, 72wk) → 20.2% vs 13.7% (p<0.001; 22.8 vs 15.0kg; ≥25% 31.6 vs 16.1%; ≥30% 19.7 vs 6.9%; waist −18.4 vs −13.0cm; AEs similar). Core SERP differentiators: the fair-dose contrast vs SURPASS-2 (sema 1mg diabetes dose), the GIP-arm mechanism, and an explicit “what it does NOT settle” section (hard outcomes/sema’s CV+kidney edge, open-label+industry-funded, lean mass, cost + retatrutide ceiling). Distinct from best-glp-1 hub (data table) and retatrutide-vs-tirzepatide (different pair). Products: tirzepatide, semaglutide, retatrutide.
  • [P3] Treatment-Regimen vs Efficacy Estimand: Why Two “Weight Loss” Numbers for the Same Drug — research-literacy explainer — Animal-to-Human Dose Conversion, GLP-1 Agonism — “treatment regimen vs efficacy estimand” (the estimand split the ranking had to compress into one paragraph — retatrutide 28.3% vs 30.3%, CagriSema 20.4% vs 22.7% — is the reason cross-trial rankings mislead; a clean Research-Literacy-pillar spoke that every news-anchored trial article can link UP to, sibling to how-to-read-peptide-studies; teaches treatment-policy vs trial-product, ITT-ish vs per-protocol intuition, why the flattering number gets quoted)
  • [P3] CagriSema and the Amylin Tier: Why Pairing GLP-1 With Amylin Is the Next Stack — peptide/mechanism — Cagrilintide, Amylin Agonism, Semaglutide — “cagrisema weight loss” (NOTE: overlaps the existing 2026-06-14 [P3] “CagriSema (Cagrilintide + Semaglutide)” backlog item — merge, don’t duplicate; the new angle from the ranking is the amylin-as-the-next-receptor-to-stack framing and REDEFINE-1 ~20.4%/22.7% data, positioning it between tirzepatide and oral sema; products cagrilintide-semaglutide, cagrilintide, retatrutide-cagrilintide)
  • NOTE: best-glp-1-for-weight-loss-2026-ranked is now the Fat Loss / Metabolic ranking hub — when TRIUMPH-2/3 (retatrutide) or any new head-to-head reads out, update its master table and the approval-status column rather than only writing a fresh news piece.

Ideas discovered (2026-06-21 engine, while writing tirzepatide-vs-semaglutide-surmount-5)

  • [DONE 2026-06-23 engine] Tirzepatide vs Semaglutide for Type 2 Diabetes: The SURPASS-2 Head-to-Head — WRITTEN as tirzepatide-vs-semaglutide-diabetes-surpass-2 (title “Tirzepatide vs Semaglutide for Diabetes: SURPASS-2”, keyword “tirzepatide vs semaglutide diabetes”). The diabetes sibling to the obesity SURMOUNT-5 page: SURPASS-2 (Frías 2021, NEJMoa2107519, NCT03987919, 40wk open-label, 1,879 T2D on metformin), tirz 5/10/15mg vs sema 1mg → tirz lower A1C every dose (15mg −2.46% vs −1.86%) + ~2× weight (−12.4kg/−13.1% vs −6.2kg/−6.7%); composite A1C≤6.5%+≥10%-loss+no-severe-hypo ~60% vs ~22%; A1C<5.7% ~51% vs ~20%. Core SERP differentiator = the dose asterisk (sema tested at 1mg, not the 2.0mg later approved via SUSTAIN FORTE) as the MIRROR-IMAGE of SURMOUNT-5’s 2.4mg, so the two head-to-heads read together show tirz ahead at sema-low AND sema-max; plus the GIP-arm mechanism and an explicit “does-not-settle” section (hard outcomes/sema’s CV+kidney edge, the 2.0mg gap, open-label+industry-funded, estimands+durability). Distinct from surmount-5 (obesity, weight primary) and best-glp-1 hub. Products: tirzepatide, semaglutide, retatrutide.
  • [P3] Does Adding GIP Actually Help? The Agonism-vs-Antagonism Paradox — mechanism explainer — GIP Agonism, GLP-1 Agonism, Tirzepatide — “gip receptor weight loss” (the counterintuitive open question the SURMOUNT-5 piece compressed into one paragraph: tirzepatide’s edge is attributed to the GIP arm, yet both GIP agonists and antagonists have shown weight-loss signals — a genuine mechanism puzzle; fills the near-empty GIP Agonism note; clean mechanism spoke under how-glp-1-works-for-weight-loss; product tirzepatide, retatrutide)
  • [P3] Open-Label vs Double-Blind: How to Trust a Head-to-Head Drug Trial — research-literacy explainer — Animal-to-Human Dose Conversion, COA — “open label vs double blind” (SURMOUNT-5 was open-label and industry-funded — the literacy gap the piece had to caveat; teaches blinding, why a measured-bodyweight primary endpoint resists expectation bias more than subjective ones, and how to weigh sponsor funding; Research-Literacy-pillar spoke every head-to-head/news-anchored article can link UP to, sibling to the pending how-to-read-clinicaltrials.gov idea)

Ideas discovered (2026-06-15 engine, while writing how-to-reconstitute-peptides)

  • [P3] Bacteriostatic Water vs Sterile Water vs Acetic Acid: Which Solvent for Which Peptide — sourcing/handling explainer — Bacteriostatic Water, Reconstitution — “bacteriostatic water vs sterile water” (some peptides — e.g. low-solubility ones — need dilute acetic acid or a specific pH, not plain BAC water; the benzyl-alcohol single-vs-multi-use distinction is high-intent; product bacteriostatic-water exists and gets a clean buy-link spoke)
  • [P3] Peptide Storage & Stability: Lyophilized vs Reconstituted, and How Long a Vial Really Lasts — handling explainer — Reconstitution, Half-life — “how long do reconstituted peptides last” (the ~28-day refrigerated window, freeze-thaw damage, light/heat; sibling to the reconstitution guide; high PAA-volume question competitors answer vaguely)
  • [P3] Net Peptide Content Calculator: Correcting Your Dose for TFA Salt — interactive/methodology micro-tool spec — Reconstitution, COA, Purity — “net peptide content calculator” (the label-mg × net-% → true-concentration correction as a standalone calculator/worked-example page; could be an artifact/tool rather than prose; only build if a tool format is wanted — otherwise the reconstitution guide already covers the math)

Ideas discovered (2026-06-18 engine, while writing tb-500-clinical-trial-first-human-cardiovascular)

  • [DONE 2026-06-22 engine] RGN-259: The Thymosin β4 Eye-Drop That Reached Phase 3 (And Why It’s Not “TB-500”) — WRITTEN as rgn-259-thymosin-beta-4-eye-drops (title “RGN-259: The Thymosin β4 Eye Drop That Isn’t TB-500”, keyword “rgn-259 thymosin beta 4”). Separated the human β4 evidence (full-length, topical, ocular) from the injected 17–23 fragment people buy, AND graded it honestly: SEER-1 NK Phase 3 (Kang 2022 IJMS, PMID 36613994, NCT02600429) was 6/10 vs 1/8 healed but the primary endpoint MISSED significance (p=0.0656, n=18, closed early); the larger confirmatory SEER-3 (European, HLB Therapeutics) FAILED its primary endpoint (stronger-than-expected placebo effect); SEER-2 (US) ongoing; the ARISE dry-eye program (3 Phase 3 trials, >1,600 pts) was mixed (some sign/symptom endpoints, no approval); RGN-259 not FDA-approved. Two-misattribution thesis: full-length≠fragment AND topical-ocular≠systemic-injection. Reinforces tb4-vs-tb-500 + the COA/trust pillar; products tb-500, thymosin-alpha-1, bpc-157-tb-500. The fragment’s own first human trial is the cardiovascular NCT07487363 (already written) — not a healing-efficacy study.
  • [P3] Why a Tissue-Repair Peptide Is Being Tested in Heart Disease: Thymosin β4 and Cardiac Repair — mechanism explainer — TB-500, Angiogenesis, Actin Regulation — “thymosin beta 4 heart repair” (the actin/migration + angiogenesis + cardiomyocyte-survival rationale behind NCT07487363, anchored to Bock-Marquette 2004 Nature; ties the Healing cluster to a cardiovascular angle; clean mechanism spoke under the new TB-500 trial article)
  • NOTE: the now-written BPC-157 (NCT07437547) and TB-500 (NCT07487363) trial pieces are a cross-linked pair. Both reinforce the long-pending [P3] “How to Read a ClinicalTrials.gov Record” literacy spoke (registered ≠ proven; Phase 1/2 safety vs efficacy; primary vs exploratory endpoints) — two consumers now; consider bumping it to P2.

Ideas discovered (2026-06-17 engine, while writing bpc-157-clinical-trial-first-human-rct)

  • [P3] How to Read a ClinicalTrials.gov Record: Phases, Endpoints & What “Recruiting” Means — research-literacy explainer — COA, Animal-to-Human Dose Conversion — “how to read clinicaltrials.gov” (the registered-≠-proven literacy gap this article kept having to caveat; teaches Phase 1/2/3, primary vs co-primary endpoints, blinding, “recruiting” vs “completed” vs “results posted”; the trust-pillar spoke every news-anchored trial article can link UP to; high evergreen value)
  • [P3] The Cancelled 2015 BPC-157 Phase 1 (PCO-02): What a Registered-Then-Vanished Trial Tells You — research/trust explainer — BPC-157, Research-Use-Only — “bpc-157 phase 1 trial” (the registered-but-never-published PCO-02 oral safety/PK study is a recurring credibility talking point; pairs with the new clinical-trial article and the COA/trust pillar; honest about why an unpublished registered trial is a yellow flag, not proof of a cover-up)
  • NOTE: the existing P2 “TB-500’s First Human Trial Is Cardiovascular” (NCT07487363) is now a natural sibling to today’s BPC-157 trial piece — when written, cross-link the two as the “2026: peptides finally enter human trials” pair.

Ideas discovered (2026-06-16 engine, while writing retatrutide-phase-3-results-triumph-1)

  • [P1] Retatrutide TRIUMPH-2 & TRIUMPH-3: The Diabetes and Cardiovascular Readouts — news-anchored follow-up — Retatrutide, SOURCE-retatrutide-triumph1-phase3 — “retatrutide diabetes trial” / “retatrutide cardiovascular” (fast-lane the moment either reads out, expected later 2026; TRIUMPH-1 was obesity-without-diabetes, so the harder T2D + established-CVD populations are the next shoe to drop; pairs with this article as the sequel, links ⇄ retatrutide-phase-3-results-triumph-1, glp-1-cancer-risk-what-2026-research-shows, retatrutide-vs-tirzepatide-comparison-2026; product retatrutide)
  • [DONE 2026-06-20 engine] GLP-1 Weight-Loss Class Ranking 2026 — WRITTEN as best-glp-1-for-weight-loss-2026-ranked (title “Best GLP-1 for Weight Loss 2026: The Class Ranked”, keyword “best glp-1 for weight loss 2026”). Built the evidence-ranked class table AND folded in the oral tier per the 2026-06-19 note: retatrutide ~28.3% (TRIUMPH-1, investigational) > tirzepatide ~22.5% (SURMOUNT-1, approved + SURMOUNT-5 head-to-head win 20.2 vs 13.7%) > CagriSema ~20.4% (REDEFINE-1, under review) > oral sema ~15.1% (OASIS-1) ≈ subQ sema ~14.9% (STEP-1, 18.7% at 7.2mg) > orforglipron ~11.2% (ATTAIN-1, approved oral non-peptide). Core differentiator vs SERP = the cross-trial/estimand/head-to-head-only methodology honesty, plus a choose-by-metric decision framework. Stayed clear of retatrutide-vs-tirzepatide (head-to-head only) and best-peptides-for-fat-loss (broad). Products: retatrutide, tirzepatide, semaglutide, cagrilintide-semaglutide.
  • [P3] Why a Triple Agonist Beats a Dual: The Glucagon Arm and Energy Expenditure — mechanism explainer — Glucagon Agonism, GLP-1 Agonism, GIP Agonism, Lipolysis — “glucagon agonist weight loss” (the counterintuitive “add the sugar-raising hormone to lose more fat” mechanism, balanced-ratio energy-expenditure thesis; clean mechanism spoke under how-glp-1-works-for-weight-loss; only the headline was covered in the Phase 3 news piece)

Ideas discovered (2026-06-14 engine, while writing how-to-read-a-peptide-coa)

  • [DONE 2026-06-15] HPLC Purity vs Net Peptide Content: Why “99% Pure” Isn’t a Full Dose — CONSUMED this run, but re-scoped. The purity-vs-content teaching half was already absorbed by the 2026-06-14 COA article (it has a full “Net peptide content” section), so writing it head-on would cannibalize. The surviving distinct value — the reconstitution-math angle the original note flagged as “high-intent and competitors barely cover it” — was executed as how-to-reconstitute-peptides-dosing-guide (keyword “how to reconstitute peptides”), which carries the TFA-salt net-content correction into an actionable dosing workflow and links UP to the COA hub. Net-content as a standalone spoke is now redundant; retire it.

  • [P3] Janoshik & Independent Peptide Testing: How to Send Your Own Vial — sourcing how-to — Purity, COA — “janoshik peptide testing” (turns the buy-bulk-and-retest best practice into an actionable walkthrough; clean trust-pillar spoke; named-lab keyword has commercial intent)

  • [P3] Compounding Pharmacy vs Research-Use-Only Peptides: The Regulatory Gap — sourcing/trust explainer — Research-Use-Only, COA — “research use only peptides meaning” (the RUO-unregulated vs compounded distinction is the trust pillar’s other half; pairs with the COA guide)

  • [P2] Retatrutide + Tesamorelin + MOTS-C: The Dual-Axis Recomposition Stack — stack guide — Retatrutide, Tesamorelin, MOTS-C — “retatrutide tesamorelin stack” (direct competitor angle: PeptideFox/RedFox/CaliforniaTrim rank for it)

  • [P3] 5-Amino-1MQ for Fat Loss: NNMT Inhibition Explained — peptide/mechanism — Lipolysis — “5-amino-1mq fat loss” (product 5-amino-1mq exists, no article yet)

  • [P3] CagriSema (Cagrilintide + Semaglutide): Amylin + GLP-1 for Fat Loss — peptide guide — Cagrilintide, Semaglutide, Amylin Agonism — “cagrisema weight loss” (products cagrilintide-semaglutide exist)

Ideas discovered (2026-06-13 engine, while writing peptide-bioavailability-by-route)

  • [RETIRED 2026-06-19 engine] Oral Semaglutide vs Orforglipron — consumed into orforglipron-foundayo-oral-glp-1-pill (the “Peptide vs Non-Peptide: Why the Molecule Matters” H2 carries the SNAC ~1–2% BA vs small-molecule ~79% divide head-on). Writing it as a standalone now would cannibalize. If a dedicated “oral semaglutide vs orforglipron” keyword page is ever wanted, re-scope to a pure oral-vs-oral decision table (dose, ritual, cost) — not the mechanism, which is now covered.
  • [P3] What Is SNAC? How Oral Peptide Delivery Actually Works — explainer — TRANSCRIPT-oral-glp1-semaglutide-vs-orforglipron, Reconstitution — “snac oral semaglutide” (permeation-enhancer mechanism + strict-administration rules; clean spoke under the bioavailability page; answers “why must I take it fasted”)
  • [P3] Subcutaneous vs Intramuscular Peptide Injection: Does the Depot Effect Matter? — explainer — Half-life, Animal-to-Human Dose Conversion — “subcutaneous vs intramuscular peptide” (the SubQ-depot vs faster-IM-absorption tradeoff and how it interacts with half-life/timing; sibling to the route page)

Ideas discovered (2026-06-12 engine, while writing animal-to-human-dose-conversion)

  • [P3] How to Read a Peptide Study: 5 Red Flags in the Methods Section — research-literacy explainer — Animal-to-Human Dose Conversion, Purity, COA — “how to read a peptide study” (sibling literacy piece to the dose-conversion hub; covers animal-only data, IP dosing, no-toxicity≠safety, sample size, route mismatch; ties methodology hub to the COA/trust pillar)
  • [P3] Start Low, Titrate Slow: A Framework for Peptide Dose Titration — protocol/explainer — Dosing & Titration, Animal-to-Human Dose Conversion — “peptide titration” (turns the step-4 safety-factor logic into a standalone framework page; links down from the methodology hub)

Ideas discovered (2026-06-11 engine, while writing tb4-vs-tb-500)

  • [P2] Is Your TB-500 Actually TB4? How to Read a Peptide COA (HPLC vs Mass-Spec) — sourcing/explainer — TRANSCRIPT-tb4-tb500-deep-dive, COA, Purity — “peptide coa how to read” (the mislabel-runs-one-direction angle generalises into a whole COA-literacy guide that every product page can link to; mass-spec-confirms-identity vs purity-% is the teaching hook; ties healing cluster to a trust/quality pillar)
  • [P3] BPC-157 vs TB-500: Which Healing Peptide for Which Injury — comparison — BPC-157, TB-500, TRANSCRIPT-tb4-tb500-deep-dive — “bpc-157 vs tb-500” (the when-to-use-which decision table from the transcript: BPC first for minor MSK, both together for acute major injury/post-surgery; distinct from the Wolverine stack article and from this TB4-vs-TB-500 identity article; product bpc-157, tb-500, bpc-157-tb-500)
  • [P3] Beta-Thymosins vs Alpha-Thymosins: TB4 vs Thymosin Alpha-1 — concept/explainer — TB-500, Thymosin Alpha-1, TRANSCRIPT-tb4-tb500-deep-dive — “thymosin alpha vs beta” (clears up the second big ‘thymosin’ confusion: structural-repair beta-thymosins vs immune-signalling alpha-thymosins; product thymosin-alpha-1, tb-500)

Ideas discovered (2026-06-10 engine, while writing how-glp-1-works-for-weight-loss)

  • [P2] Does GLP-1 Burn Fat or Just Cut Appetite? — explainer — GLP-1 Agonism, Lipolysis, Retatrutide — “does glp-1 burn fat” (high-intent PAA keyword; the appetite-vs-energy-expenditure distinction, with retatrutide’s glucagon arm as the one real thermogenic exception; clean spoke under the new mechanism page)
  • [P3] What Is “Food Noise” and How Do GLP-1s Quiet It? — explainer — GLP-1 Agonism — “food noise glp-1” (mesolimbic reward-pathway angle; fast-growing search term competitors cover only superficially; links up to the new mechanism page)
  • [P2] Why GLP-1 Weight Loss Plateaus — And What Multi-Receptor Peptides Do About It — mechanism/comparison — GLP-1 Agonism, GIP Agonism, Glucagon Agonism, Tirzepatide, Retatrutide — “glp-1 weight loss plateau” (deepens the single-receptor-ceiling thesis into its own page; ties GIP + glucagon arms together)

Ideas discovered (2026-06-09 engine, while writing cjc-1295-dac-vs-no-dac)

  • [DONE 2026-06-24 engine] MK-677 vs CJC-1295 With DAC: The Two Peptides That Flatten Your GH Curve — WRITTEN as mk-677-vs-cjc-1295 (title “MK-677 vs CJC-1295: The Flat-Curve Problem (2026)”, keyword “mk-677 vs cjc-1295”). Core SERP differentiator the ranking pages all miss: “CJC-1295” is TWO compounds — reframed the whole comparison around which one, then exposed MK-677 + CJC-1295-DAC as mechanistic twins (both elevate the trough — ~3.5× vs ~7.5× — flat curve, opposite of the amplitude aging erodes), with no-DAC the pulsatile outlier. Honest evidence-grading is the second hook: MK-677 is the MOST human-studied GH secretagogue yet looks WORST (Nass 2008 2-yr RCT — +1.1kg FFM but NO strength gain + worsened insulin sensitivity; Adunsky 2011 hip-fracture phase-IIb stopped early on a CHF signal 6.5% vs 1.7%), while CJC-DAC has only tiny phase-1 PK (Teichman 2006) + a death-terminated unpublished phase-2. Covered the popular CJC-DAC-weekly+MK-677-nightly combo as the least-defensible “double-flat” stack vs the physiologic GHRH+ipamorelin alternative. Diversified away from the over-saturated Fat Loss/Healing clusters into the underserved GH-Axis. Links UP to cjc-1295-dac-vs-no-dac (pulse-amplitude explainer) + how-to-choose-growth-hormone-peptide-2026 (pillar); products mk-677-capsules, cjc-1295-dac, cjc-1295-no-dac, ipamorelin, sermorelin.

Ideas discovered (2026-06-24 engine, while writing mk-677-vs-cjc-1295)

  • [P3] Ibutamoren & Insulin Resistance: The Glucose Cost of Oral GH — safety/mechanism explainer — MK-677, GH Secretagogue, IGF-1 Signaling — “mk-677 insulin resistance” (the +fasting-glucose / declined-insulin-sensitivity finding from Nass 2008 that the comparison piece compressed into one line; a high-intent fear keyword competitors answer vaguely; ghrelin-receptor-agonism→glucose mechanism; clean spoke under mk-677-vs-cjc-1295 and the peptide-safety pillar; product mk-677-capsules)
  • [P3] Do GH Secretagogues Strain the Heart? The MK-677 CHF Signal & the CJC-1295 Trial Death — safety/trust explainer — MK-677, CJC-1295, Research-Use-Only — “mk-677 heart” / “gh secretagogue cardiac safety” (the TWO cardiac datapoints this piece raised — the Adunsky hip-fracture CHF signal 6.5% vs 1.7% and the unpublished death-terminated CJC-1295-DAC phase-2 — pulled into one honestly-graded cardiac-safety piece, careful to note both were in older/comorbid populations, not healthy users; reinforces the peptide-safety pillar; links ⇄ mk-677-vs-cjc-1295, cjc-1295-dac-vs-no-dac, peptide-side-effects-safety-guide-2026)
  • NOTE: GH-Axis now has a clean trio — how-to-choose-growth-hormone-peptide-2026 (pillar) ⇄ cjc-1295-dac-vs-no-dac (pulse-amplitude) ⇄ mk-677-vs-cjc-1295 (flat-curve head-to-head). [P2] “GHRH + GHRP Synergy” is now WRITTEN (2026-06-25, ghrh-ghrp-synergy-why-stack-gh-peptides); and [P2] “Why GH Peptides Are Dosed at Night Before Sleep” is now also WRITTEN (2026-06-26, growth-hormone-peptide-timing) — the GH-Axis cluster is now a quintet (pillar ⇄ amplitude ⇄ flat-curve ⇄ why-stack ⇄ when/timing). Best remaining unblocked GH-Axis spokes are now the two new concept/comparison ideas from the timing run (somatostatin standalone; basal-vs-pulsatile) plus the GHRP-add-on bake-off.
  • [P3] Basal vs Pulsatile GH: Why the Shape of the Signal Matters More Than the Peak — concept explainer — PAPER-veldhuis-2012-pulsatile-growth-hormone-secretion, TRANSCRIPT-gh-peptide-selection-deep-dive — “pulsatile growth hormone” (the AMPK/sirtuin-trough vs mTOR/IGF-1 longevity framing as a standalone concept page the whole GH cluster can link up to; concept candidates: somatopause, GH pulse amplitude)

Ideas discovered (2026-06-08 engine, while writing how-to-choose-growth-hormone-peptide)

  • [DONE 2026-06-26 engine] Why GH Peptides Are Dosed at Night Before Sleep — WRITTEN as growth-hormone-peptide-timing (title “Growth Hormone Peptide Timing: Why Night Dosing (2026)”, keyword “growth hormone peptide timing”). The when spoke that completes the GH-Axis quartet→quintet. Core SERP differentiator competitors miss: anchored on PRIMARY human sleep-GH physiology, not just “inject before bed” — Takahashi 1968 (PMID 5675428: GH pulse appears with deep-sleep onset, is delayed when sleep onset is delayed, and a re-sleep after waking triggers a fresh pulse) + Van Cauter & Plat 1996 (PMID 8627466: ~70% of nocturnal GH pulses coincide with slow-wave sleep). Three-reason night rationale (somatostatin nadir / ride the body’s biggest pulse / less desensitization), the empty-stomach half (food→somatostatin+insulin, ~60% blunting labeled educational), the 30–45-min-peak vs 30–90-min-deep-sleep-onset timing arithmetic, the long-acting/oral EXCEPTION (CJC-DAC + MK-677 flat-curve → timing matters less — the SERP’s biggest blind spot), and the secretagogue-≠-rhGH-timing distinction (Levshtein 2025 PMID 40034226). Links ⇄ ghrh-ghrp-synergy-why-stack-gh-peptides, how-to-choose-growth-hormone-peptide-2026, cjc-1295-dac-vs-no-dac, mk-677-vs-cjc-1295, hgh-peptide-therapy-benefits-risks-vs-secretagogues-2026, peptide-side-effects-safety-guide-2026; products sermorelin, cjc-1295-no-dac, ipamorelin, tesamorelin, cjc-1295-no-dac-ipamorelin, ipamorelin-tesamorelin, cjc-1295-dac, mk-677-capsules, melatonin.

Ideas discovered (2026-06-07 engine, while writing how-to-keep-muscle-on-glp-1)

  • [P2] GLP-1 Body Recomposition Data: Semaglutide vs Tirzepatide vs Retatrutide (DXA Evidence Review) — comparison/explainer — Semaglutide, Tirzepatide, Retatrutide, GLP-1 Agonism — “tirzepatide lean mass loss” (STEP-1 ~40% vs SURMOUNT-1 ~25% lean fraction is a clean, data-led angle; Look 2025 DOM substudy is fresh ammunition)
  • [P3] Protein Intake on GLP-1s: Why Appetite Suppression Breaks Your Diet — explainer — GLP-1 Agonism, STACK-fat-loss — “protein intake on glp-1” (PAA-heavy informational keyword; supports the muscle-preservation spoke)

Ideas discovered (2026-06-06 engine, while writing bpc-157-tb-500-stack)

  • [P2] The “Glow”/“KLOW” Stack: BPC-157 + TB-500 + GHK-Cu for Skin & Scar Repair — stack guide — STACK-healing, GHK-Cu, BPC-157, TB-500 — “glow peptide stack” (products glow-blend/klow-blend exist; natural pillar-sibling to the Wolverine article)

Ideas discovered (2026-06-05 engine, while writing glp-1-cancer-risk)

  • [P2] Does Semaglutide Cause Thyroid Cancer? The Rodent-vs-Human Evidence — mechanism/safety explainer — Semaglutide, GLP-1 Agonism — “does semaglutide cause thyroid cancer” (high-intent fear keyword; rodent-C-cell vs human-receptor-expression evidence answers it cleanly; deepens the new GLP-1-cancer article)
  • [P3] GLP-1 vs DPP-4 Inhibitors: Same Incretin System, Different Outcomes — comparison/explainer — GLP-1 Agonism — “glp-1 vs dpp-4” (DPP-4 was the ASCO 2026 cancer comparator; clean teaching angle on why drug class matters)
  • [P3] GLP-1s and Longevity: The Anti-Inflammatory, Anti-Senescence Case — mechanism/longevity — GLP-1 Agonism, STACK-longevity, TRANSCRIPT-top5-longevity-peptides — “glp-1 longevity” (ties the 1-longevity ranking + cancer-protective signal into the Longevity pillar)

Ideas discovered (2026-06-25 engine, while writing ghrh-ghrp-synergy-why-stack-gh-peptides)

  • [P3] Somatostatin: The GH Brake You’re Actually Fighting — mechanism explainer — GH Secretagogue, Ghrelin-GHRP Agonism — “somatostatin growth hormone” (the inhibitory-tone half of the axis the synergy piece kept invoking — why eating doubles it within ~2h and blunts GH ~60%, why night dosing works (lowest somatostatin), why GHRPs partly release the brake, and the arginine-blunts-somatostatin trick; clean concept spoke the whole GH cluster links up to; no catalog product, pure education)
  • [P3] GHRP-2 vs GHRP-6 vs Hexarelin vs Ipamorelin: Picking the Add-On — comparison — GHRP-2, GHRP-6, Hexarelin, Ipamorelin, PAPER-raun-1998-ipamorelin-the-first-selective — “ghrp-2 vs ghrp-6 vs ipamorelin” (the synergy piece establishes you need a GHRP but argues ipamorelin only in passing; a dedicated add-on bake-off on potency/appetite/cortisol-prolactin/selectivity/cardiac (hexarelin’s post-CABG signal) would convert four near-empty product notes into a buyable comparison; products ipamorelin, ghrp-2, ghrp-6, hexarelin)
  • NOTE: with ghrh-ghrp-synergy-why-stack-gh-peptides written, GH-Axis is now a quartet — how-to-choose-growth-hormone-peptide-2026 (pillar) ⇄ cjc-1295-dac-vs-no-dac (amplitude) ⇄ mk-677-vs-cjc-1295 (flat-curve) ⇄ ghrh-ghrp-synergy-why-stack-gh-peptides (the why-stack mechanism). The two thin legacy CJC+ipamorelin articles (cjc-1295-ipamorelin-stack-gold-standard-gh-release, cjc1295-ipamorelin-synergistic-gh-release) should each add an UP-link to this new mechanism page on their next edit; the synergy page already links DOWN to the gold-standard protocol. [P2] “Why GH Peptides Are Dosed at Night Before Sleep” is now WRITTEN (2026-06-26, growth-hormone-peptide-timing); the GH-Axis cluster is now a quintet: how-to-choose-growth-hormone-peptide-2026 (pillar) ⇄ cjc-1295-dac-vs-no-dac (amplitude) ⇄ mk-677-vs-cjc-1295 (flat-curve) ⇄ ghrh-ghrp-synergy-why-stack-gh-peptides (why-stack) ⇄ growth-hormone-peptide-timing (when). Next-best unblocked GH-Axis spokes: the standalone “Somatostatin: the GH brake” concept page and “Basal vs Pulsatile GH” (both now have a second consumer in the timing piece), and the GHRP add-on bake-off.

Rules

  • Don’t duplicate an existing Articles/ slug — check first.
  • Prefer P1 physician-protocol and stack pieces early; they showcase our unique sources.
  • When the Radar adds a P0 (e.g. “BPC-157 human trial positive”), the engine should take it next run.

Graph View

Backlinks